Zhongnan Medical Journal Press

Home Results

A total of 12 result was found. Results that relate to ZHANG Wen

Review and risk information management of neuropathy induced by emerging anti-tumor drugs

Published on Chinese Journal of Pharmacoepidemiology 2024,33(1):9-18.
11678 times 2235 times

LYU Feng SONG Wei XIN Mengru XIE Di ZHANG Wenqing HE Wen HU Hankun

Emerging anti-tumor drugs Drug-induced neuropathy Drug risk information management
Details
Correlation study of neutrophils in knee osteoarthritis

Published on New Medicine 2024,34(3):347-354.
11781 times 2618 times

LIU Xin GUO Jiajun MA Hong'e ZHANG Wenxian

Knee osteoarthritis Neutrophils MicroRNAs Exosomes Treatment
Details
Efgartigimod alfa in the treatment of generalized myasthenia gravis: a rapid health technology assessment

Published on Chinese Journal of Pharmacoepidemiology 2024,33(10):1156-1163.
12198 times 2408 times

HUANG Gerile LI Yujie ZHANG Wenjing GUO Hao

Efgartigimod alfa Myasthenia gravis Rapid health technology assessment Efficaey Safety Economy
Details
Signal mining and analysis of adverse events for lecanemab based on the FAERS database

Published on Chinese Journal of Pharmacoepidemiology 2025,34(2):166-174.
12697 times 2123 times

ZHANG Wen LI Min LIU Erping TAO Wenting CAI Rui ZHOU Weixian

Lecanemab FAERS database Drug adverse events Signal mining
Details
Dorzagliatin in the treatment of type 2 diabetes：a rapid health technology assessment

Published on Chinese Journal of Pharmacoepidemiology 2025,34(4):448-455.
19324 times 3591 times

LI Yujie ZHANG Wenjing YANG Hongxin GUO Hao

Dorzagliatin Type 2 diabetes mellitus Rapid health technology assessment Efficacy Safety Economy
Details
Trends in the burden of spinal cord injury in China from 1990 to 2021

Published on New Medicine 2025,35(7):810-818.
16490 times 2149 times

CAI Yan CHEN Yuan ZHANG Wenxi

Disease burden Spinal cord injury Age-standardized incidence rate Age-standardized prevalence rate Age-period-cohort effect Trend analysis
Details
Search strategies for systematic review and Meta-analysis: from PICO to large language models

Published on Journal of Mathematical Medicine 2026,39(1):2-11.
5102 times 1219 times

HUANG Sidie CUI Nuan ZHANG Wen ZENG Yidi LI Lin LI Jinxia LIANG Hao

Systematic review Meta-analysis Retrieval strategy PICO Large language models
Details
Mepolizumab for refractory chronic rhinosinusitis with nasal polyps: a rapid health technology assessment

Published on Chinese Journal of Pharmacoepidemiology 2026,35(2):192-199.
6493 times 1096 times

GU Shilong ZHANG Wenjing GUO Hao

Mepolizumab Refractory chronic rhinosinusitis with nasal polyps Effectiveness safety Cost-effectiveness
Details
Construction of a risk prediction model for fertility anxiety in female thyroid cancer patients of reproductive age

Published on New Medicine 2026,36(4):399-406.
2482 times 934 times

PENG Jingjun PENG Yuxia ZHANG Wenling HONG Xiaoting LI Yuyu

Reproductive age Thyroid cancer Fertility anxiety Risk prediction model
Details
The interaction effect of family function and school life satisfaction on depression and anxiety of youth in school

Published on New Medicine 2026,36(5):503-510.
1728 times 497 times

CHEN Yuanfan ZHANG Wenge TAN Jianfeng WU Jiayuan HU Liren

Family function School life satisfaction Youth Depression Anxiety
Details
Post-marketing safety evaluation of nirsevimab based on the FAERS database

Published on Chinese Journal of Pharmacoepidemiology 2026,35(6):653-659.
1695 times 421 times

NIU Rui LIU Wei ZHAO Kai ZHANG Wenqian ZHAO Fang

Nirsevimab Respiratory syncytial virus Pharmacovigilance Adverse drug reactions
Details
Meta-analysis of efficacy and safety of pertuzumab biosimilars versus original drug in the treatment of patients with HER2-positive breast cancer

Published on Chinese Journal of Pharmacoepidemiology 2026,35(7):810-817.
982 times 306 times

GU Shilong ZHANG Wenjing GUO Hao

Pertuzumab Biosimilars Original drug HER2 Breast cancer Efficacy Safety Meta-analysis
Details